FEP Medical Policy Manual

FEP 2.04.62 Multimarker Serum Testing Related to Ovarian Cancer

Annual Effective Policy Date: April 1, 2024

Original Policy Date: December 2011

Related Policies:

2.04.66 - Serum Biomarker Human Epididymis Protein 4

Multimarker Serum Testing Related to Ovarian Cancer

Description

Description

A variety of serum biomarkers have been studied for their association with ovarian cancer. Of particular interest have been tests that integrate results from multiple analytes into a risk score to predict the presence of disease. Three tests based on this principle, OVA1, Overa (the second-generation OVA1 test), and the Risk of Ovarian Malignancy Algorithm (ROMA) have been cleared by the U.S. Food and Drug Administration. The intended use of OVA1 and Overa is as an aid to further assess whether malignancy is present in a patient with an ovarian adnexal mass who has not yet been referred to an oncologist, even when the physician"s independent clinical and radiologic evaluation does not indicate malignancy. The intended use of ROMA is as an aid, in conjunction with clinical assessment, to assess whether a premenopausal or a postmenopausal woman who presents with an ovarian adnexal mass and has not yet been referred to an oncologist is at a high or low likelihood of finding malignancy on surgery.

OBJECTIVE

The objective of this evidence review is to evaluate whether multimarker serum testing related to ovarian cancer improves the net health outcome in patients undergoing surgery for ovarian cancer.

POLICY STATEMENT

All uses of the OVA1, Overa, and ROMA tests are **investigational**, including but not limited to:

1. preoperative evaluation of adnexal masses to triage for malignancy, OR

2. screening for ovarian cancer, OR

3. selecting individuals for surgery for an adnexal mass, OR

4. evaluation of individuals with clinical or radiologic evidence of malignancy, OR

5. evaluation of individuals with nonspecific signs or symptoms suggesting possible malignancy, OR

6. postoperative testing and monitoring to assess surgical outcome and/or to detect recurrent malignant disease following treatment.

POLICY GUIDELINES

OVA1, Overa, and ROMA tests are combinations of several separate lab tests and involve proprietary algorithms for determining risk (ie, what CPT calls multianalyte assays with algorithmic analyses [MAAAs]).

BENEFIT APPLICATION

Experimental or investigational procedures, treatments, drugs, or devices are not covered (See General Exclusion Section of brochure).

FDA REGULATORY STATUS

In July 2009, the OVA1® test (Aspira Labs [Austin, TX]) was cleared for marketing by the FDA through the 510(k) process. OVA1® was designed as a tool to further assess the likelihood that malignancy is present when the physician's independent clinical and radiologic evaluation does not indicate malignancy.

In September 2011, the Risk of Ovarian Malignancy Algorithm (ROMA™ test; Fujirebio Diagnostics [Sequin, TX]) was cleared for marketing by the FDA through the 510(k) process. The intended use of ROMA™ is as an aid, in conjunction with clinical assessment, in assessing whether a premenopausal or postmenopausal woman who presents with an ovarian adnexal mass is at a high or low likelihood of finding malignancy on surgery.

In March 2016, a second-generation test called Overa™ (also referred to as next-generation OVA1®), in which 2 of the 5 biomarkers in OVA1® are replaced with human epididymis secretory protein 4 and follicle-stimulating hormone, was cleared for marketing by the FDA through the 510(k) process. Similar to OVA1®, Overa™ generates a low- or high-risk of malignancy on a scale from 0 to 10.

Three multimarker serum-based tests specific to ovarian cancer have been cleared by the U.S. Food and Drug Administration (FDA) with the intended use of triaging patients with adnexal masses (see Regulatory Status section). These tests are summarized in Table 1. The proposed use of the tests is to identify women with a substantial likelihood of malignant disease who may benefit from referral to a gynecologic oncology specialist. Patients with positive results may be considered candidates for referral to a gynecologic oncologist for treatment. The tests have been developed and evaluated only in patients with adnexal masses and planned surgeries. Other potential uses, such as selecting patients to have surgery, screening asymptomatic patients, and monitoring treatment, have not been investigated. Furthermore, the tests are not intended to be used as stand-alone tests, but in conjunction with clinical assessment.

Other multimarker panels and longitudinal screening algorithms are under development; however, these are not yet commercially available.[14,15,]

Table 1. Summary of FDA-Cleared Multimarker Serum-Based Tests Specific to Ovarian Cancer

Variables	OVA1	Overa	ROMA
Cleared	2009	2016	2011
Manufacturer	Quest Diagnostics	Vermillion	Roche Diagnostics
Biomarkers used			
CA 125 II	X	X	X
b_2-microglobulin	X		
Transferrin	X	X	
Transthyretin	X		
Apolipoprotein AI	X	X	
HE4		X	X
FSH		X	
Score range	0 to 10	0 to 10	0 to 10
Risk categorization			
Premenopausal	<5.0: low ≥5.0: high	<5.0: low ≥5.0: high	≥1.3: high
Postmenopausal	<4.4: low ≥4.4: high		≥2.77: high

CA 125: cancer antigen 125; FDA: U.S. Food and Drug Administration; FSH: follicle-stimulating hormone; HE4: human epididymis secretory protein 4; ROMA: Risk of Ovarian Malignancy Algorithm.

Black Box Warning

In December 2011, the FDA amended its regulation for classifying ovarian adnexal mass assessment score test systems. The change required that off-label risks be highlighted using a black box warning. The warning is intended to mitigate the risk to health associated with off-label use as a screening test, stand-alone diagnostic test, or as a test to determine whether to proceed with surgery. Considering the history and currently unmet medical needs for ovarian cancer testing, the FDA concluded that there is a risk of off-label use of this device.[16,] To address this risk, the FDA requires that manufacturers provide notice concerning the risks of off-label uses in the labeling, advertising, and promotional material of ovarian adnexal mass assessment score test systems. Manufacturers must address the following risks:

- Women without adnexal pelvic masses (ie, for cancer "screening") are not part of the intended use population for the ovarian adnexal mass assessment score test systems. Public health risks associated with false-positive results for ovarian cancer screening tests are well described in the medical literature and include morbidity or mortality associated with unneeded testing and surgery. The risk from false-negative screening results also includes morbidity and mortality due to failure to detect and treat ovarian malignancy.

- Analogous risks, adjusted for prevalence and types of disease, arise if test results are used to determine the need for surgery in patients who are known to have ovarian adnexal masses.

- If used outside the "OR" rule that is described in this special control guidance, results from ovarian adnexal mass assessment score test systems pose a risk for morbidity and mortality due to nonreferral for oncologic evaluation and treatment.

RATIONALE

Summary of Evidence

For individuals who have adnexal mass(es) undergoing surgery for possible ovarian cancer who receive multimarker serum testing with clinical assessment preoperatively to assess ovarian cancer risk, the evidence includes studies assessing technical performance and diagnostic accuracy. Relevant outcomes are overall survival and test accuracy. OVA1 and Overa are intended for use in patients for whom clinical assessment does not clearly indicate cancer. When used in this manner, sensitivity for ovarian malignancy was 92% and specificity was 42% with OVA1; with Overa, sensitivity was 94% and specificity was 65%. Risk of Ovarian Malignancy Algorithm (ROMA) is intended for use with clinical assessment, but no specific method has been defined. One study, which used clinical assessment and ROMA results, showed a sensitivity of 90% and specificity of 67%. However, the National Comprehensive Cancer Network guidelines recommend (category 2A) that all patients with suspected ovarian cancer should be evaluated by an experienced gynecologic oncologist. Given the National Comprehensive Cancer Network recommendation, direct evidence will be required to demonstrate that the use of U.S. Food and Drug Administration (FDA) cleared multimarker serum testing to inform decisions regarding referral to a gynecologic oncology specialist for surgery has clinical usefulness. Direct evidence of clinical usefulness is provided by studies that have compared health outcomes for patients managed with and without the FDA cleared multimarker serum testing. Because these are intervention studies, the preferred evidence would be from randomized controlled trials. No trials were identified that have evaluated whether referral based on FDA cleared multimarker serum testing improves health outcomes. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

SUPPLEMENTAL INFORMATION

Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in 'Supplemental Information" if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

American College of Obstetricians and Gynecologists

In 2017, with reaffirmation in 2019 and 2021, the American College of Obstetricians and Gynecologists (ACOG) opinion on the role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer addressed using multimarker serum testing.[37,] The opinion states that multimarker panels lack strong evidence for use in asymptomatic women without adnexal masses and do not improve early detection and survival rates in average-risk women. The Society for Gynecologic Oncology endorsed this ACOG opinion.

In 2016, an ACOG Practice Bulletin addressing the evaluation and management of adnexal masses made a level B recommendation (based on limited or inconsistent scientific evidence) that consultation with or referral to a gynecologic oncologist is recommended for premenopausal or postmenopausal with an elevated score on a formal risk assessment test such as the multivariate index assay, risk of malignancy index, or the Risk of Ovarian Malignancy Algorithm, or 1 of the ultrasound-based scoring systems from the International Ovarian Tumor Analysis group.[13,] A level C recommendation (based on consensus and expert opinion) was given to using serum biomarker panels as an alternative to cancer antigen 125 (CA 125) level to decide about the referral to a gynecologic oncologist for an adnexal mass requiring surgery.

National Institute for Health and Care Excellence

In 2011, the National Institute for Health and Care Excellence issued guidance on the identification and management of ovarian cancer.[38,] The guideline does not provide any recommendations regarding additional serum marker testing besides testing for serum CA 125 levels in women with symptoms suggestive of ovarian cancer.

National Comprehensive Cancer Network

The National Comprehensive Cancer Network (NCCN) guideline on ovarian cancer (v. 2.2023) includes the following statement[39]:

The FDA has approved the use of ROMA, OVA1, and OVERA for estimating the risk for ovarian cancer in women with an adnexal mass for which surgery is planned, and have not been referred to an oncologist. Although the American Congress of Obstetricians and Gynecologists (ACOG) has suggested that ROMA and OVA1 may be useful for deciding which patients to refer to a gynecologic oncologist, other professional organizations have been non-committal. Not all studies have found that multi-biomarker assays improve all metrics (ie, sensitivity, specificity, positive predictive value, negative predictive value) for prediction of malignancy compared with other methods (eg, imaging, single-biomarker tests, symptom index/clinical assessment). Currently, the NCCN Panel does not recommend the use of these biomarker tests for determining the status of an undiagnosed adnexal/pelvic mass.

In addition, the guideline states "based on data documenting increased survival, the NCCN Guidelines Panel recommends that all patients with suspected malignancies (especially those with an adnexal mass) should undergo evaluation by an experienced gynecologic oncologist prior to surgery."

U.S. Preventive Services Task Force Recommendations

In 2018, the U.S. Preventive Services Task Force recommended against screening asymptomatic women for ovarian cancer (D recommendation). [40,] The Task Force has not addressed multimarker serum testing related to ovarian cancer.

Medicare National Coverage

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

REFERENCES

1. Surveillance Epidemology and End Results (SEER) Program. SEER Stat Fact Sheets: Ovarian Cancer. n.d.; https://seer.cancer.gov/statfacts/html/ovary.html. Accessed October 31, 2023.
2. du Bois A, Rochon J, Pfisterer J, et al. Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review. Gynecol Oncol. Feb 2009; 112(2): 422-36. PMID 18990435
3. Matthews BJ, Qureshi MM, Fiascone SJ, et al. Racial disparities in non-recommendation of adjuvant chemotherapy in stage II-III ovarian cancer. Gynecol Oncol. Jan 2022; 164(1): 27-33. PMID 34785030
4. Zhang C, Zhang C, Wang Q, et al. Differences in Stage of Cancer at Diagnosis, Treatment, and Survival by Race and Ethnicity Among Leading Cancer Types. JAMA Netw Open. Apr 01 2020; 3(4): e202950. PMID 32267515
5. Joslin CE, Brewer KC, Davis FG, et al. The effect of neighborhood-level socioeconomic status on racial differences in ovarian cancer treatment in a population-based analysis in Chicago. Gynecol Oncol. Nov 2014; 135(2): 285-91. PMID 25173584
6. Mattei LH, Robb L, Banning K, et al. Enrollment of Individuals From Racial and Ethnic Minority Groups in Gynecologic Cancer Precision Oncology Trials. Obstet Gynecol. Oct 01 2022; 140(4): 654-661. PMID 36075065
7. Zhong P, Yang B, Pan F, et al. Temporal trends in Black-White disparities in cancer surgery and cancer-specific survival in the United States between 2007 and 2015. Cancer Med. Feb 2023; 12(3): 3509-3519. PMID 35968573
8. Ellis L, Canchola AJ, Spiegel D, et al. Racial and Ethnic Disparities in Cancer Survival: The Contribution of Tumor, Sociodemographic, Institutional, and Neighborhood Characteristics. J Clin Oncol. Jan 01 2018; 36(1): 25-33. PMID 29035642
9. Albright BB, Nasioudis D, Craig S, et al. Impact of Medicaid expansion on women with gynecologic cancer: a difference-in-difference analysis. Am J Obstet Gynecol. Feb 2021; 224(2): 195.e1-195.e17. PMID 32777264
10. Bodurtha Smith AJ, Applebaum J, Fader AN. Association of the Affordable Care Act's Medicaid Expansion With 1-Year Survival Among Patients With Ovarian Cancer. Obstet Gynecol. Jun 01 2022; 139(6): 1123-1129. PMID 35675609
11. Smick AH, Holbert M, Neff R. Association of Physician Densities and Gynecologic Cancer Outcomes in the United States. Obstet Gynecol. Nov 01 2022; 140(5): 751-757. PMID 36201771
12. Van Holsbeke C, Van Belle V, Leone FP, et al. Prospective external validation of the 'ovarian crescent sign' as a single ultrasound parameter to distinguish between benign and malignant adnexal pathology. Ultrasound Obstet Gynecol. Jul 2010; 36(1): 81-7. PMID 20217895
13. Eskander R, Berman M, Keder L. Practice Bulletin No. 174: Evaluation and Management of Adnexal Masses. Obstet Gynecol. Nov 2016; 128(5): e210-e226. PMID 27776072
14. Simmons AR, Clarke CH, Badgwell DB, et al. Validation of a Biomarker Panel and Longitudinal Biomarker Performance for Early Detection of Ovarian Cancer. Int J Gynecol Cancer. Jul 2016; 26(6): 1070-7. PMID 27206285
15. Yanaranop M, Tiyayon J, Siricharoenthai S, et al. Rajavithi-ovarian cancer predictive score (R-OPS): A new scoring system for predicting ovarian malignancy in women presenting with a pelvic mass. Gynecol Oncol. Jun 2016; 141(3): 479-484. PMID 26996662

16. Guidance for Industry and FDA Staff - Class II Special Controls Guidance Document: Ovarian Adnexal Mass Assessment Score Test System. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/class-ii-special-controls-guidance-document-ovarian-adnexal-mass-assessment-score-test-system. Updated February 27, 2018. Accessed October 31, 2023.
17. Fung ET. A recipe for proteomics diagnostic test development: the OVA1 test, from biomarker discovery to FDA clearance. Clin Chem. Feb 2010; 56(2): 327-9. PMID 20110452
18. U.S. Food and Drug Administration (FDA). 510(k) Substantial Equivalence Determination Decision Summary: OVA1TM Test (K081754) n.d.; https://www.accessdata.fda.gov/cdrh_docs/reviews/K081754.pdf. Accessed October 28, 2023.
19. Grenache DG, Heichman KA, Werner TL, et al. Clinical performance of two multi-marker blood tests for predicting malignancy in women with an adnexal mass. Clin Chim Acta. Jan 01 2015; 438: 358-63. PMID 25283731
20. Bristow RE, Smith A, Zhang Z, et al. Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay. Gynecol Oncol. Feb 2013; 128(2): 252-9. PMID 23178277
21. Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. Feb 2008; 108(2): 402-8. PMID 18061248
22. Moore RG, Miller MC, Disilvestro P, et al. Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. Obstet Gynecol. Aug 2011; 118(2 Pt 1): 280-288. PMID 21775843
23. Suri A, Perumal V, Ammalli P, et al. Diagnostic measures comparison for ovarian malignancy risk in Epithelial ovarian cancer patients: a meta-analysis. Sci Rep. Aug 27 2021; 11(1): 17308. PMID 34453074
24. Dayyani F, Uhlig S, Colson B, et al. Diagnostic Performance of Risk of Ovarian Malignancy Algorithm Against CA125 and HE4 in Connection With Ovarian Cancer: A Meta-analysis. Int J Gynecol Cancer. Nov 2016; 26(9): 1586-1593. PMID 27540691
25. Wang J, Gao J, Yao H, et al. Diagnostic accuracy of serum HE4, CA125 and ROMA in patients with ovarian cancer: a meta-analysis. Tumour Biol. Jun 2014; 35(6): 6127-38. PMID 24627132
26. Al Musalhi K, Al Kindi M, Al Aisary F, et al. Evaluation of HE4, CA-125, Risk of Ovarian Malignancy Algorithm (ROMA) and Risk of Malignancy Index (RMI) in the Preoperative Assessment of Patients with Adnexal Mass. Oman Med J. Sep 2016; 31(5): 336-44. PMID 27602187
27. Cho HY, Park SH, Park YH, et al. Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women. J Korean Med Sci. Dec 2015; 30(12): 1777-83. PMID 26713052
28. Terlikowska KM, Dobrzycka B, Witkowska AM, et al. Preoperative HE4, CA125 and ROMA in the differential diagnosis of benign and malignant adnexal masses. J Ovarian Res. Jul 19 2016; 9(1): 43. PMID 27436085
29. Shen Y, Zhao L, Lu S. Diagnostic performance of HE4 and ROMA among Chinese women. Clin Chim Acta. Jan 2020; 500: 42-46. PMID 31626761
30. Shin KH, Kim HH, Kwon BS, et al. Clinical Usefulness of Cancer Antigen (CA) 125, Human Epididymis 4, and CA72-4 Levels and Risk of Ovarian Malignancy Algorithm Values for Diagnosing Ovarian Tumors in Korean Patients With and Without Endometriosis. Ann Lab Med. Jan 2020; 40(1): 40-47. PMID 31432638
31. Dunton C, Bullock RG, Fritsche H. Multivariate Index Assay Is Superior to CA125 and HE4 Testing in Detection of Ovarian Malignancy in African-American Women. Biomark Cancer. 2019; 11: 1179299X19853785. PMID 31236012
32. Han KH, Park NH, Kim JJ, et al. The power of the Risk of Ovarian Malignancy Algorithm considering menopausal status: a comparison with CA 125 and HE4. J Gynecol Oncol. Nov 2019; 30(6): e83. PMID 31576682
33. Carreras-Dieguez N, Glickman A, Munmany M, et al. Comparison of HE4, CA125, ROMA and CPH-I for Preoperative Assessment of Adnexal Tumors. Diagnostics (Basel). Jan 17 2022; 12(1). PMID 35054393
34. Chacn E, Das J, Caballero C, et al. Risk of Ovarian Malignancy Algorithm versus Risk Malignancy Index-I for Preoperative Assessment of Adnexal Masses: A Systematic Review and Meta-Analysis. Gynecol Obstet Invest. 2019; 84(6): 591-598. PMID 31311023
35. Davenport C, Rai N, Sharma P, et al. Menopausal status, ultrasound and biomarker tests in combination for the diagnosis of ovarian cancer in symptomatic women. Cochrane Database Syst Rev. Jul 26 2022; 7(7): CD011964. PMID 35879201
36. Moore RG, Hawkins DM, Miller MC, et al. Combining clinical assessment and the Risk of Ovarian Malignancy Algorithm for the prediction of ovarian cancer. Gynecol Oncol. Dec 2014; 135(3): 547-51. PMID 25449569
37. Committee Opinion No. 716: The Role of the Obstetrician-Gynecologist in the Early Detection of Epithelial Ovarian Cancer in Women at Average Risk. Obstet Gynecol. Sep 2017; 130(3): e146-e149. PMID 28832487
38. National Center for Clinical Excellence (NICE). Ovarian cancer: recognition and initial management [CG122]. 2011; https://www.nice.org.uk/guidance/cg122. Accessed October 31, 2023.
39. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer Including Fallopian Tub Cancer and Primary Peritoneal Cancer. Version 2.2023. https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf. Accessed October 31, 2023.
40. Grossman DC, Curry SJ, Owens DK, et al. Screening for Ovarian Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. Feb 13 2018; 319(6): 588-594. PMID 29450531

POLICY HISTORY - THIS POLICY WAS APPROVED BY THE FEP® PHARMACY AND MEDICAL POLICY COMMITTEE ACCORDING TO THE HISTORY BELOW:

Date	Action	Description
December 2011	New policy	
March 2013	Replace policy	Policy update with literature search, results of TEC assessment. References 7, 13, and 17-28 added, Policy statement changed to not medically necessary for preoperative evaluation.
March 2014	Replace policy	Policy updated with literature search. References 14, 15 and 20 added; other references renumbered or removed. No change to policy statement. Title changed to Proteomic based Testing Related to Ovarian Cancer.
March 2015	Replace policy	Policy updated with literature review through September 25, 2014. References 1, 14, 18 and 24 added. Policy statement unchanged.
March 2018	Replace policy	Policy update with literature through October 16, 2017; references 1, 8-10, 12, 14, 16-21, and 27 were added. Policy statement changed with addition of the Overa test. Title changed to "Multimarker Serum Testing Related to Ovarian Cancer,
March 2019	Replace policy	Policy updated with literature review through October 30, 2018; reference 25 updated. Policy statement is unchanged.
March 2020	Replace policy	Policy updated with literature review through October 19,2019; references added. Policy statement unchanged.
March 2021	Replace policy	Policy updated with literature review through October 30, 2020; references added. Policy statement unchanged.
March 2022	Replace policy	Policy updated with literature review through October 27, 2021; references added. Policy statement unchanged.
March 2023	Replace policy	Policy updated with literature review through November 4, 2022; references added. Minor editorial refinements to policy statements; intent unchanged.
March 2024	Replace policy	Policy updated with literature review through October 31, 2023; no references added. Policy statement unchanged.